Lupin in the news
Pharmaceutical formulations and ingredients
Tamtam found 20 recent articles about Lupin.
- Lupin Receives US FDA Approval for Amifampridine Tablets, 10 mg
Lupin secured US FDA approval for its Amifampridine Tablets, 10 mg, expanding its generic product line and qualifying for 180 days of shared market exclusivity.
- Lupin stock: Postal ballot seeks approval for Akhil Gupta's board seat
Lupin is seeking shareholder approval for Akhil Gupta's appointment as an independent director for a five-year term.
- Stock Picks Today: NSE, ABB India, Lupin, Syrma And More On Brokerages' Radar
Brokerages issued fresh calls and outlooks on diverse stocks like NSE, ABB India, Lupin, Anupam Rasayan, and Syrma SGS, across sectors such as pharma, capital goods, and IT services.
- Lupin: Nomura raises target price to Rs 2,780, sees nearly 40% upside as valuations turn attractive
Nomura increased Lupin's target price to Rs 2,780, forecasting a significant upside due to attractive valuations and strong future growth prospects.
- Lupin seeks shareholder approval for Akhil Gupta's independent director role
Lupin Limited seeks shareholder approval for Akhil Gupta's appointment as an Independent Director for a five-year term starting November 3, 2026, requiring a special resolution due to his age.
- Buzzing stocks: Meesho, Clean Max, Lupin, IOC, NBCC, NCL Ind, Zee, Edelweiss, Jujhar Logistics, Ola
Lupin's biosimilar Ranluspec has been launched in Europe by Sandoz, expanding access to treatments for retinal diseases.
- Lupin Launches Ranibizumab Biosimilar Across Europe in Partnership with Sandoz
Lupin, in partnership with Sandoz, has launched its ranibizumab biosimilar, Ranluspec, in Europe to treat various retinal conditions.
- Lupin launches biosimilar Ranibizumab in Europe
Lupin launched its biosimilar Ranibizumab, Ranluspec™, in Europe, excluding Germany, to treat retinal diseases.
- Lupin announces European launch of biosimilar Ranluspec
Lupin, in partnership with Sandoz, launched its biosimilar Ranluspec (Ranibizumab) in Europe to treat retinal diseases.
- Lupin Announces European Launch of Biosimilar Ranibizumab - Lupin | Press Release
Lupin's biosimilar Ranibizumab, RanluspecTM, is now available in most of Europe through its partner Sandoz, offering a new treatment option for retinal diseases.
- European Commission Approves Lupin’s Ranibizumab Biosimilar
Lupin's biosimilar Ranluspec received European Commission approval and was launched in most European markets by partner Sandoz.
- Lupin’s partner debuts ranibizumab biosimilar in Europe
Lupin's partner Sandoz launched the ranibizumab biosimilar Ranluspec in Europe (excluding Germany) to treat ocular disorders.
- Pharma sector stocks today, November 11: Alembic Pharma gains 2.82%; Divi's Laboratories falls 2.08%, Lupin down 1.25%
Pharmaceutical stocks showed mixed performance on November 11, 2026, with Alembic Pharma gaining and Divi's Laboratories and Lupin declining.
- Lupin Targets Complex Drugs To Drive Next Phase Of Growth, Plans Higher U.S. Manufacturing
Lupin experienced mixed financial results in Q2FY27 with revenue growth but decreased profit, while expanding its US generic product portfolio and focusing on complex drugs.
- Accumulate Lupin; target of Rs 2250: Prabhudas Lilladher
Lupin's Q2FY27 EBITDA fell 8% year-over-year, with future profit decline anticipated due to increased competition for key products despite some pipeline opportunities.
- Broker’s Call: Lupin (Accumulate)
Lupin's Q2-FY27 EBITDA decreased while revenue grew, driven by strong US sales, though increased competition for key products is expected to impact future profits.
- Lupin Q2 Review: Systematix Revises Target Price, Remains Cautious On US Recovery
Lupin's Q2 revenue beat estimates driven by developed markets and India, but Systematix remains cautious on its US recovery and near-term profitability.
- Lupin Q2 Review: Jefferies Cuts Target 15%, Flags US Competition; Kotak Retains Add
Lupin's Q2 profitability was impacted by increased US competition, leading Jefferies to cut its target price, while Kotak maintained its rating, anticipating growth in India.
- Propranolol: Cardinol LA 160 mg is changing to Propranolol LA Lupin
A funded brand change from Cardinol LA 160 mg to Propranolol LA Lupin has occurred due to discontinuation, with a temporary supply issue for the new brand expected to resolve by mid-November 2026.
- Lupin Q2 net profit falls 22.19% to ₹1,155.3 crore
Lupin's Q2 net profit fell by 22.19% to ₹1,155.3 crore due to an exceptional item, despite a rise in revenue from operations.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Lupin?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies